Insider Buying: AgomAb Therapeutics (NASDAQ:AGMB) CFO Acquires $85,900.00 in Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) CFO Pierre Kemula acquired 10,000 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were bought at an average price of $8.59 per share, with a total value of $85,900.00. Following the transaction, the chief financial officer directly owned 10,000 shares in the company, valued at approximately $85,900. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

AgomAb Therapeutics Stock Performance

Shares of NASDAQ AGMB opened at $9.08 on Friday. The stock’s fifty day simple moving average is $12.60 and its 200 day simple moving average is $11.93. AgomAb Therapeutics NV has a 52-week low of $7.97 and a 52-week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. Analysts predict that AgomAb Therapeutics NV will post -1.76 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating on the stock. HC Wainwright reissued a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, September 16th. B. Riley Financial began coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price for the company. Finally, Piper Sandler began coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.